Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA9 | Q16790 | 4/20 | 0.50 |
| ▸ | GALR3 | O60755 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.43 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.43 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL917252 | 0.91 | GALR3 (0.61) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL917254 | 0.91 | GALR3 (0.61) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL916613 | 0.85 | KDM4E (0.55) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL916611 | 0.85 | KDM4E (0.55) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL917553 | 0.85 | ALDH1A1 (0.54) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL917552 | 0.85 | ALDH1A1 (0.54) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL918014 | 0.78 | GALR3 (0.63) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL918013 | 0.78 | GALR3 (0.63) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL8165591 | 0.77 | GALR3 (0.81) | ALDH1A1PKMKDM4ECA12CA2 | |
| SCHEMBL8404733 | 0.77 | ALDH1A1 (0.55) | ALDH1A1PKMKDM4ECA2GALR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2010-07-15 | — | — | US | disclosed |
| US-7642281-B2 | Indolone compounds useful to treat cognitive impairment | HELICON THERAPEUTICS, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2009-12-24 | — | — | US | disclosed |
| US-7465750-B2 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | H. LUNDBECK A/S (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080039496-A1 | Method of Modulating Neurite Outgrowth by the use of a Galanin-3 Receptor Antagonist | HELICON THERAPEUTICS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | BLACKBURN THOMAS P | 2007-11-08 | — | — | US | disclosed |
| US-20070135510-A1 | Indolone Compounds Useful To Treat Cognitive Impairment | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2007-06-14 | — | — | US | disclosed |
| US-7220775-B2 | Compound useful for the treatment of neuropathic pain | H. LUNDBECK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2004-05-13 | — | — | US | disclosed |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318504-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | ALDH1A1 1921/4885PKM 1909/4885KDM4E 4396/4885 |
| US-20080039496-A1 | Method of Modulating Neurite Outgrowth by the use of a Galanin-3 Receptor Antagonist | GALR3, GALR2, GAP43 | ALDH1A1 3677/4885PKM 4500/4885KDM4E 4306/4885 |
| US-20100179187-A1 | INDOLONE COMPOUNDS USEFUL TO TREAT COGNITIVE IMPAIRMENT | CHAT, AANAT, TPH2 | ALDH1A1 2040/4885PKM 3600/4885KDM4E 2813/4885 |
| US-20030078271-A1 | Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | ALDH1A1 1921/4885PKM 1909/4885KDM4E 4396/4885 |
| US-20040092570-A1 | GAL3 antagonists for the treatment of neuropathic pain | GALR3, GALR2, GALR1 | ALDH1A1 3303/4885PKM 3138/4885KDM4E 4395/4885 |
| US-20070135510-A1 | Indolone Compounds Useful To Treat Cognitive Impairment | CHAT, AANAT, TPH2 | ALDH1A1 2040/4885PKM 3600/4885KDM4E 2813/4885 |
| US-20070259942-A1 | Use of GAL3 antagonist for treatment of depression and/or anxiety and compounds useful in such methods | GALR3, GALR2, GALR1 | ALDH1A1 1882/4885PKM 1871/4885KDM4E 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.